Strategies for Conjugation of Biomolecules to Nanoparticles as Tumor Targeting Agents

Sajjad       Molavipordanjani; Seyed    Jalal    Hosseinimehr
Abstract

Combination of nanotechnology, biochemistry, chemistry and biotechnology provides the opportunity to design unique nanoparticles for tumor targeting, drug delivery, medical imaging and biosensing. Nanoparticles conjugated with biomolecules such as antibodies, peptides, vitamins and aptamer can resolve current challenges including low accumulation, internalization and retention at the target site in cancer diagnosis and therapy through active targeting. In this review, we focus on different strategies for conjugation of biomolecules to nanoparticles such as inorganic nanoparticles (iron oxide, gold, silica and carbon nanoparticles), liposomes, lipid and polymeric nanoparticles and their application in tumor targeting.
Keywords: Nanoparticles, biofunctionalization, active targeting, click chemistry, nanotechnology, tumor targeting.
[1] 
Koo KM, Mainwaring PN, Tomlins SA, Trau M. Merging new-age biomarkers and nanodiagnostics for precision prostate cancer management. Nat Rev Urol  2019; 16(5): 302-17.
[http://dx.doi.org/10.1038/s41585-019-0178-2] [PMID:  30962568] 
[2] 
Mauter MS, Zucker I, Perreault F, Werber JR, Kim J-H, Elimelech M. The role of nanotechnology in tackling global water challenges. Nature Sustainability  2018; 1(4): 166-75.
[http://dx.doi.org/10.1038/s41893-018-0046-8] 
[3] 
Zhang RX, Li J, Zhang T, et al. Importance of integrating nanotechnology with pharmacology and physiology for innovative drug delivery and therapy - an illustration with firsthand examples. Acta Pharmacol Sin  2018; 39(5): 825-44.
[http://dx.doi.org/10.1038/aps.2018.33] [PMID:  29698389] 
[4] 
Adiseshaiah PP, Crist RM, Hook SS, McNeil SE. Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer. Nat Rev Clin Oncol  2016; 13(12): 750-65.
[http://dx.doi.org/10.1038/nrclinonc.2016.119] [PMID:  27531700] 
[5] 
Senapati S, Mahanta AK, Kumar S, Maiti P. Controlled drug delivery vehicles for cancer treatment and their performance. Signal Transduct Target Ther  2018; 3(1): 7.
[http://dx.doi.org/10.1038/s41392-017-0004-3] [PMID:  29560283] 
[6] 
Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer  2017; 17(1): 20-37.
[http://dx.doi.org/10.1038/nrc.2016.108] [PMID:  27834398] 
[7] 
Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov  2008; 7(9): 771-82.
[http://dx.doi.org/10.1038/nrd2614] [PMID:  18758474] 
[8] 
Schroeder A, Heller DA, Winslow MM, et al. Treating metastatic cancer with nanotechnology. Nat Rev Cancer  2011; 12(1): 39-50.
[http://dx.doi.org/10.1038/nrc3180] [PMID:  22193407] 
[9] 
Mangal S, Gao W, Li T, Zhou QT. Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities. Acta Pharmacol Sin  2017; 38(6): 782-97.
[http://dx.doi.org/10.1038/aps.2017.34] [PMID:  28504252] 
[10] 
Bazak R, Houri M, El Achy S, Kamel S, Refaat T. Cancer active targeting by nanoparticles: a comprehensive review of literature. J Cancer Res Clin Oncol  2015; 141(5): 769-84.
[http://dx.doi.org/10.1007/s00432-014-1767-3] [PMID:  25005786] 
[11] 
Sakurai Y, Kajimoto K, Hatakeyama H, Harashima H. Advances in an active and passive targeting to tumor and adipose tissues. Expert Opin Drug Deliv  2015; 12(1): 41-52.
[http://dx.doi.org/10.1517/17425247.2015.955847] [PMID:  25376864] 
[12] 
Kaklotar D, Agrawal P, Abdulla A, et al. Transition from passive to active targeting of oral insulin nanomedicines: enhancement in bioavailability and glycemic control in diabetes. Nanomedicine (Lond)  2016; 11(11): 1465-86.
[http://dx.doi.org/10.2217/nnm.16.43] [PMID:  27171572] 
[13] 
Swain S, Sahu PK, Beg S, Babu SM. Nanoparticles for cancer targeting: current and future directions. Curr Drug Deliv  2016; 13(8): 1290-302.
[http://dx.doi.org/10.2174/1567201813666160713121122] [PMID:  27411485] 
[14] 
Nakamura H, Fang J, Maeda H. Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls. Expert Opin Drug Deliv  2015; 12(1): 53-64.
[http://dx.doi.org/10.1517/17425247.2014.955011] [PMID:  25425260] 
[15] 
Kalyane D, Raval N, Maheshwari R, Tambe V, Kalia K, Tekade RK. Employment of enhanced permeability and retention effect (EPR): nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer. Mater Sci Eng C  2019; 98: 1252-76.
[http://dx.doi.org/10.1016/j.msec.2019.01.066] [PMID:  30813007] 
[16] 
Jiang W, von Roemeling C A, Chen Y, et al. Designing nanomedicine for immuno-oncology Nat Biomed Eng 2017; 1: 0029.
[http://dx.doi.org/10.1038/s41551-017-0029] 
[17] 
Muhamad N, Plengsuriyakarn T, Na-Bangchang K. Application of active targeting nanoparticle delivery system for chemotherapeutic drugs and traditional/herbal medicines in cancer therapy: a systematic review. Int J Nanomedicine  2018; 13: 3921-35.
[http://dx.doi.org/10.2147/IJN.S165210] [PMID:  30013345] 
[18] 
Alavi M, Hamidi M. Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles. Drug Metab Pers Ther  2019; 34(1)
[http://dx.doi.org/10.1515/dmpt-2018-0032] [PMID:  30707682] 
[19] 
Satpathy M, Zielinski R, Lyakhov I, Yang L. Optical imaging of ovarian cancer using HER-2 affibody conjugated nanoparticles. Methods Mol Biol  2015; 1219: 171-85.
[http://dx.doi.org/10.1007/978-1-4939-1661-0_13] [PMID:  25308269] 
[20] 
Zhang Y, Jiang S, Zhang D, Bai X, Hecht SM, Chen S. DNA-affibody nanoparticles for inhibiting breast cancer cells overexpressing HER2. Chem Commun (Camb)  2017; 53(3): 573-6.
[http://dx.doi.org/10.1039/C6CC08495H] [PMID:  27975087] 
[21] 
Tan H, Huang Y, Xu J, et al. Spider toxin peptide lycosin-I functionalized gold nanoparticles for in vivo tumor targeting and therapy. Theranostics  2017; 7(12): 3168-78.
[http://dx.doi.org/10.7150/thno.19780] [PMID:  28839471] 
[22] 
Xiong H, Du S, Zhang P, Jiang Z, Zhou J, Yao J. Primary tumor and pre-metastatic niches co-targeting “peptides-lego” hybrid hydroxyapatite nanoparticles for metastatic breast cancer treatment. Biomater Sci  2018; 6(10): 2591-604.
[http://dx.doi.org/10.1039/C8BM00706C] [PMID:  30187035] 
[23] 
Li H, Guo L, Huang A, et al. Nanoparticle-conjugated aptamer targeting hnRNP A2/B1 can recognize multiple tumor cells and inhibit their proliferation. Biomaterials  2015; 63: 168-76.
[http://dx.doi.org/10.1016/j.biomaterials.2015.06.013] [PMID:  26107993] 
[24] 
Harris MA, Pearce TR, Pengo T, Kuang H, Forster C, Kokkoli E. Aptamer micelles targeting fractalkine-expressing cancer cells in vitro and in vivo. Nanomedicine (Lond)  2018; 14(1): 85-96.
[http://dx.doi.org/10.1016/j.nano.2017.08.020] [PMID:  28912042] 
[25] 
Wang X, Wei B, Cheng X, Wang J, Tang R. 3-Carboxyphenylboronic acid-modified carboxymethyl chitosan nanoparticles for improved tumor targeting and inhibitory. Eur J Pharm Biopharm  2017; 113: 168-77.
[http://dx.doi.org/10.1016/j.ejpb.2016.12.034] [PMID:  28089786] 
[26] 
Ravindran A, Chandran P, Khan SS. Biofunctionalized silver nanoparticles: advances and prospects. Colloids Surf B Biointerfaces  2013; 105: 342-52.
[http://dx.doi.org/10.1016/j.colsurfb.2012.07.036] [PMID:  23411404] 
[27] 
Tugarova AV, Kamnev AA. Proteins in microbial synthesis of selenium nanoparticles. Talanta  2017; 174: 539-47.
[http://dx.doi.org/10.1016/j.talanta.2017.06.013] [PMID:  28738620] 
[28] 
Miao Z, Gao Z, Chen R, Yu X, Su Z, Wei G. Surface-bioengineered gold nanoparticles for biomedical applications. Curr Med Chem  2018; 25(16): 1920-44.
[http://dx.doi.org/10.2174/0929867325666180117111404] [PMID:  29345568] 
[29] 
Gulsuner HU, Ceylan H, Guler MO, Tekinay AB. Multi-domain short peptide molecules for in situ synthesis and biofunctionalization of gold nanoparticles for integrin-targeted cell uptake. ACS Appl Mater Interfaces  2015; 7(20): 10677-83.
[http://dx.doi.org/10.1021/acsami.5b00093] [PMID:  25942540] 
[30] 
Ermini ML, Chadtová Song X, Špringer T, Homola J. Peptide functionalization of gold nanoparticles for the detection of carcinoembryonic antigen in blood plasma via SPR-Based biosensor. Front Chem  2019; 7: 40.
[http://dx.doi.org/10.3389/fchem.2019.00040] [PMID:  30778384] 
[31] 
Chen Y, Xianyu Y, Jiang X. Surface modification of gold nanoparticles with small molecules for biochemical analysis. Acc Chem Res  2017; 50(2): 310-9.
[http://dx.doi.org/10.1021/acs.accounts.6b00506] [PMID:  28068053] 
[32] 
Nel AE, Mädler L, Velegol D, et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater  2009; 8(7): 543-57.
[http://dx.doi.org/10.1038/nmat2442] [PMID:  19525947] 
[33] 
Conde J, Dias JT, Grazú V, Moros M, Baptista PV, de la Fuente JM. Revisiting 30 years of biofunctionalization and surface chemistry of inorganic nanoparticles for nanomedicine. Front Chem  2014; 2: 48.
[http://dx.doi.org/10.3389/fchem.2014.00048] [PMID:  25077142] 
[34] 
Bose RJ, Lee SH, Park H. Biofunctionalized nanoparticles: an emerging drug delivery platform for various disease treatments. Drug Discov Today  2016; 21(8): 1303-12.
[http://dx.doi.org/10.1016/j.drudis.2016.06.005] [PMID:  27297732] 
[35] 
Kwon KC, Ko HK, Lee J, Lee EJ, Kim K, Lee J. Enhanced in vivo tumor detection by active tumor cell targeting using multiple tumor receptor-binding peptides presented on genetically engineered human ferritin nanoparticles. Small  2016; 12(31): 4241-53.
[http://dx.doi.org/10.1002/smll.201600917] [PMID:  27356892] 
[36] 
Chen F, Hong H, Shi S, et al. Engineering of hollow mesoporous silica nanoparticles for remarkably enhanced tumor active targeting efficacy. Sci Rep  2014; 4: 5080.
[http://dx.doi.org/10.1038/srep05080] [PMID:  24875656] 
[37] 
Yu DH, Lu Q, Xie J, Fang C, Chen HZ. Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature. Biomaterials  2010; 31(8): 2278-92.
[http://dx.doi.org/10.1016/j.biomaterials.2009.11.047] [PMID:  20053444] 
[38] 
Kumar S, Aaron J, Sokolov K. Directional conjugation of antibodies to nanoparticles for synthesis of multiplexed optical contrast agents with both delivery and targeting moieties. Nat Protoc  2008; 3(2): 314-20.
[http://dx.doi.org/10.1038/nprot.2008.1] [PMID:  18274533] 
[39] 
Manjappa AS, Chaudhari KR, Venkataraju MP, et al. Antibody derivatization and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumor. J Control Release  2011; 150(1): 2-22.
[http://dx.doi.org/10.1016/j.jconrel.2010.11.002] [PMID:  21095210] 
[40] 
Su CW, Yen CS, Chiang CS, Hsu CH, Chen SY. Multistage continuous targeting with quantitatively controlled peptides on chitosan-lipid nanoparticles with multicore-shell nanoarchitecture for enhanced orally administrated anticancer in vitro and in vivo. Macromol Biosci  2017; 17(2)
[http://dx.doi.org/10.1002/mabi.201600260] [PMID:  27634372] 
[41] 
Okur AC, Erkoc P, Kizilel S. Targeting cancer cells via tumor-homing peptide CREKA functional PEG nanoparticles. Colloids Surf B Biointerfaces  2016; 147: 191-200.
[http://dx.doi.org/10.1016/j.colsurfb.2016.08.005] [PMID:  27513587] 
[42] 
Gao H, Zhang Q, Yang Y, Jiang X, He Q. Tumor homing cell penetrating peptide decorated nanoparticles used for enhancing tumor targeting delivery and therapy. Int J Pharm  2015; 478(1): 240-50.
[http://dx.doi.org/10.1016/j.ijpharm.2014.11.029] [PMID:  25448586] 
[43] 
Jiang Y, Yang N, Zhang H, et al. Enhanced in vivo antitumor efficacy of dual-functional peptide-modified docetaxel nanoparticles through tumor targeting and Hsp90 inhibition. J Control Release  2016; 221: 26-36.
[http://dx.doi.org/10.1016/j.jconrel.2015.11.029] [PMID:  26643616] 
[44] 
Feng X, Yao J, Gao X, et al. Multi-targeting peptide-functionalized nanoparticles recognized vasculogenic mimicry, tumor neovasculature, and glioma cells for enhanced anti-glioma therapy. ACS Appl Mater Interfaces  2015; 7(50): 27885-99.
[http://dx.doi.org/10.1021/acsami.5b09934] [PMID:  26619329] 
[45] 
Cheng YJ, Zhang AQ, Hu JJ, He F, Zeng X, Zhang XZ. Multifunctional peptide-amphiphile end-capped mesoporous silica nanoparticles for tumor targeting drug delivery. ACS Appl Mater Interfaces  2017; 9(3): 2093-103.
[http://dx.doi.org/10.1021/acsami.6b12647] [PMID:  28032742] 
[46] 
Iyer G, Pinaud F, Xu J, et al. Aromatic aldehyde and hydrazine activated peptide coated quantum dots for easy bioconjugation and live cell imaging. Bioconjug Chem  2011; 22(6): 1006-11.
[http://dx.doi.org/10.1021/bc100593m] [PMID:  21553893] 
[47] 
Joshi PP, Yoon SJ, Hardin WG, Emelianov S, Sokolov KV. Conjugation of antibodies to gold nanorods through Fc portion: synthesis and molecular specific imaging. Bioconjug Chem  2013; 24(6): 878-88.
[http://dx.doi.org/10.1021/bc3004815] [PMID:  23631707] 
[48] 
Kolb HC, Finn MG, Sharpless KB. Click chemistry: diverse chemical function from a few good reactions. Angew Chem Int Ed Engl  2001; 40(11): 2004-21.
[http://dx.doi.org/10.1002/1521-3773(20010601)40:11<2004:AID-ANIE2004>3.0.CO;2-5] [PMID:  11433435] 
[49] 
Hoyle CE, Bowman CN. Thiol-ene click chemistry. Angew Chem Int Ed Engl  2010; 49(9): 1540-73.
[http://dx.doi.org/10.1002/anie.200903924] [PMID:  20166107] 
[50] 
Rubio N, Mei KC, Klippstein R, et al. Solvent-free click-mechanochemistry for the preparation of cancer cell targeting graphene oxide. ACS Appl Mater Interfaces  2015; 7(34): 18920-3.
[http://dx.doi.org/10.1021/acsami.5b06250] [PMID:  26278410] 
[51] 
Paka GD, Ramassamy C. Optimization of curcumin-loaded PEG-PLGA nanoparticles by GSH functionalization: investigation of the internalization pathway in neuronal cells. Mol Pharm  2017; 14(1): 93-106.
[http://dx.doi.org/10.1021/acs.molpharmaceut.6b00738] [PMID:  27744707] 
[52] 
Wang L, Neoh KG, Kang ET, Shuter B. Multifunctional polyglycerol-grafted Fe3O4@SiO2 nanoparticles for targeting ovarian cancer cells. Biomaterials  2011; 32(8): 2166-73.
[http://dx.doi.org/10.1016/j.biomaterials.2010.11.042] [PMID:  21146869] 
[53] 
Hou Y, Qiao R, Fang F, et al. NaGdF4 nanoparticle-based molecular probes for magnetic resonance imaging of intraperitoneal tumor xenografts in vivo. ACS Nano  2013; 7(1): 330-8.
[http://dx.doi.org/10.1021/nn304837c] [PMID:  23199030] 
[54] 
Liu Y, Hou W, Sun H, et al. Thiol-ene click chemistry: a biocompatible way for orthogonal bioconjugation of colloidal nanoparticles. Chem Sci (Camb)  2017; 8(9): 6182-7.
[http://dx.doi.org/10.1039/C7SC01447C] [PMID:  28989650] 
[55] 
Choi J, Rustique E, Henry M, et al. Targeting tumors with cyclic RGD-conjugated lipid nanoparticles loaded with an IR780 NIR dye: in vitro and in vivo evaluation. Int J Pharm  2017; 532(2): 677-85.
[http://dx.doi.org/10.1016/j.ijpharm.2017.03.007] [PMID:  28279737] 
[56] 
Kuang Y, Jiang X, Zhang Y, et al. Dual functional peptide-driven nanoparticles for highly efficient glioma-targeting and drug codelivery. Mol Pharm  2016; 13(5): 1599-607.
[http://dx.doi.org/10.1021/acs.molpharmaceut.6b00051] [PMID:  27058780] 
[57] 
Moses JE, Moorhouse AD. The growing applications of click chemistry. Chem Soc Rev  2007; 36(8): 1249-62.
[http://dx.doi.org/10.1039/B613014N] [PMID:  17619685] 
[58] 
Noureddine A, Gary-Bobo M, Lichon L, et al. Bis-clickable mesoporous silica nanoparticles: straightforward preparation of light-actuated nanomachines for controlled drug delivery with active targeting. Chemistry  2016; 22(28): 9624-30.
[http://dx.doi.org/10.1002/chem.201600870] [PMID:  27258427] 
[59] 
Hou J, Zhang Q, Li X, et al. Synthesis of novel folate conjugated fluorescent nanoparticles for tumor imaging. J Biomed Mater Res A  2011; 99(4): 684-9.
[http://dx.doi.org/10.1002/jbm.a.33187] [PMID:  21913319] 
[60] 
Guldris N, Gallo J. García-Hevia L, Rivas J, Bañobre-López M, Salonen LM. Orthogonal clickable iron oxide nanoparticle platform for targeting, imaging, and on-demand release. Chemistry  2018; 24(34): 8624-31.
[http://dx.doi.org/10.1002/chem.201800389] [PMID:  29645299] 
[61] 
Lai CH, Chang TC, Chuang YJ, Tzou DL, Lin CC. Stepwise orthogonal click chemistry toward fabrication of paclitaxel/galactose functionalized fluorescent nanoparticles for HepG2 cell targeting and delivery. Bioconjug Chem  2013; 24(10): 1698-709.
[http://dx.doi.org/10.1021/bc400219t] [PMID:  23987828] 
[62] 
Liu R, Zhao J, Han G, et al. Click-functionalized SERS nanoprobes with improved labeling efficiency and capability for cancer cell imaging. ACS Appl Mater Interfaces  2017; 9(44): 38222-9.
[http://dx.doi.org/10.1021/acsami.7b10409] [PMID:  28920430] 
[63] 
Deshayes S, Maurizot V, Clochard MC, et al. “Click” conjugation of peptide on the surface of polymeric nanoparticles for targeting tumor angiogenesis. Pharm Res  2011; 28(7): 1631-42.
[http://dx.doi.org/10.1007/s11095-011-0398-5] [PMID:  21374102] 
[64] 
Zhang C, Pan D, Li J, et al. Enzyme-responsive peptide dendrimer-gemcitabine conjugate as a controlled-release drug delivery vehicle with enhanced antitumor efficacy. Acta Biomater  2017; 55: 153-62.
[http://dx.doi.org/10.1016/j.actbio.2017.02.047] [PMID:  28259838] 
[65] 
Wang CF, Mäkilä EM, Kaasalainen MH, et al. Copper-free azide-alkyne cycloaddition of targeting peptides to porous silicon nanoparticles for intracellular drug uptake. Biomaterials  2014; 35(4): 1257-66.
[http://dx.doi.org/10.1016/j.biomaterials.2013.10.065] [PMID:  24211082] 
[66] 
Kakwere H, Ingham ES, Allen R, et al. Toward personalized peptide-based cancer nanovaccines: a facile and versatile synthetic approach. Bioconjug Chem  2017; 28(11): 2756-71.
[http://dx.doi.org/10.1021/acs.bioconjchem.7b00502] [PMID:  28956907] 
[67] 
Sun P, Yuan P, Wang G, et al. High density glycopolymers functionalized perylene diimide nanoparticles for tumor-targeted photoacoustic imaging and enhanced photothermal therapy. Biomacromolecules  2017; 18(10): 3375-86.
[http://dx.doi.org/10.1021/acs.biomac.7b01029] [PMID:  28850778] 
[68] 
Chan DP, Deleavey GF, Owen SC, Damha MJ, Shoichet MS. Click conjugated polymeric immuno-nanoparticles for targeted siRNA and antisense oligonucleotide delivery. Biomaterials  2013; 34(33): 8408-15.
[http://dx.doi.org/10.1016/j.biomaterials.2013.07.019] [PMID:  23932248] 
[69] 
Klein PM, Kern S, Lee DJ, et al. Folate receptor-directed orthogonal click-functionalization of siRNA lipopolyplexes for tumor cell killing in vivo. Biomaterials  2018; 178: 630-42.
[http://dx.doi.org/10.1016/j.biomaterials.2018.03.031] [PMID:  29580727] 
[70] 
Yoon HY, Shin ML, Shim MK, et al. Artificial chemical reporter targeting strategy using bioorthogonal click reaction for improving active-targeting efficiency of tumor. Mol Pharm  2017; 14(5): 1558-70.
[http://dx.doi.org/10.1021/acs.molpharmaceut.6b01083] [PMID:  28191852] 
[71] 
Logie J, Ganesh AN, Aman AM, Al-Awar RS, Shoichet MS. Preclinical evaluation of taxane-binding peptide-modified polymeric micelles loaded with docetaxel in an orthotopic breast cancer mouse model. Biomaterials  2017; 123: 39-47.
[http://dx.doi.org/10.1016/j.biomaterials.2017.01.026] [PMID:  28161682] 
[72] 
Wang LL, Balakrishnan A, Bigall NC, et al. A bio-chemosynthetic approach to superparamagnetic iron oxide-ansamitocin conjugates for use in magnetic drug targeting. Chemistry  2017; 23(10): 2265-70.
[http://dx.doi.org/10.1002/chem.201604903] [PMID:  27935144] 
[73] 
Brand C, Iacono P, Pérez-Medina C, Mulder WJM, Kircher MF, Reiner T. Specific binding of liposomal nanoparticles through inverse electron-demand diels-alder click chemistry. ChemistryOpen  2017; 6(5): 615-9.
[http://dx.doi.org/10.1002/open.201700105] [PMID:  29046855] 
[74] 
von Maltzahn G, Ren Y, Park JH, et al. In vivo tumor cell targeting with “click” nanoparticles. Bioconjug Chem  2008; 19(8): 1570-8.
[http://dx.doi.org/10.1021/bc800077y] [PMID:  18611045] 
[75] 
Zuo H, Chen W, Cooper HM, Xu ZP. A facile way of modifying layered double hydroxide nanoparticles with targeting ligand-conjugated albumin for enhanced delivery to brain tumour cells. ACS Appl Mater Interfaces  2017; 9(24): 20444-53.
[http://dx.doi.org/10.1021/acsami.7b06421] [PMID:  28574700] 
[76] 
Yu X, Song Y, Di Y, He H, Fu D, Jin C. Enhanced tumor targeting of cRGD peptide-conjugated albumin nanoparticles in the BxPC-3 cell line. Sci Rep  2016; 6: 31539.
[http://dx.doi.org/10.1038/srep31539] [PMID:  27515795] 
[77] 
Cui W, Li J, Decher G. Self-assembled smart nanocarriers for targeted drug delivery. Adv Mater  2016; 28(6): 1302-11.
[http://dx.doi.org/10.1002/adma.201502479] [PMID:  26436442] 
[78] 
Ruiz-Hitzky E, Darder M, Aranda P, Ariga K. Advances in biomimetic and nanostructured biohybrid materials. Adv Mater  2010; 22(3): 323-36.
[http://dx.doi.org/10.1002/adma.200901134] [PMID:  20217713] 
[79] 
Ko S, Liu H, Chen Y, Mao C. DNA nanotubes as combinatorial vehicles for cellular delivery. Biomacromolecules  2008; 9(11): 3039-43.
[http://dx.doi.org/10.1021/bm800479e] [PMID:  18821795] 
[80] 
Li J, Pei H, Zhu B, et al. Self-assembled multivalent DNA nanostructures for noninvasive intracellular delivery of immunostimulatory CpG oligonucleotides. ACS Nano  2011; 5(11): 8783-9.
[http://dx.doi.org/10.1021/nn202774x] [PMID:  21988181] 
[81] 
Hamblin GD, Carneiro KM, Fakhoury JF, Bujold KE, Sleiman HF. Rolling circle amplification-templated DNA nanotubes show increased stability and cell penetration ability. J Am Chem Soc  2012; 134(6): 2888-91.
[http://dx.doi.org/10.1021/ja2107492] [PMID:  22283197] 
[82] 
Lee H, Lytton-Jean AK, Chen Y, et al. Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nat Nanotechnol  2012; 7(6): 389-93.
[http://dx.doi.org/10.1038/nnano.2012.73] [PMID:  22659608] 
[83] 
Qi W, Wang A, Yang Y, et al. The lectin binding and targetable cellular uptake of lipid-coated polysaccharide microcapsules. J Mater Chem  2010; 20(11): 2121-7.
[http://dx.doi.org/10.1039/b920469p] 
[84] 
Du C, Zhao J, Fei J, et al. Alginate-based microcapsules with a molecule recognition linker and photosensitizer for the combined cancer treatment. Chem Asian J  2013; 8(4): 736-42.
[http://dx.doi.org/10.1002/asia.201201088] [PMID:  23401337] 
[85] 
Cui W, Cui Y, Zhao J, Li J. Fabrication of tumor necrosis factor-related apoptosis inducing ligand (TRAIL)/ALG modified CaCO3 as drug carriers with the function of tumor selective recognition. J Mater Chem B Mater Biol Med  2013; 1(9): 1326-32.
[http://dx.doi.org/10.1039/c2tb00293k] 
[86] 
Ke R, Vishnoi K, Viswakarma N, et al. Involvement of AMP-activated protein kinase and death receptor 5 in TRAIL-Berberine-induced apoptosis of cancer cells. Sci Rep  2018; 8(1): 5521.
[http://dx.doi.org/10.1038/s41598-018-23780-x] [PMID:  29615720] 
[87] 
Wuttke S, Lismont M, Escudero A, Rungtaweevoranit B, Parak WJ. Positioning metal-organic framework nanoparticles within the context of drug delivery - A comparison with mesoporous silica nanoparticles and dendrimers. Biomaterials  2017; 123: 172-83.
[http://dx.doi.org/10.1016/j.biomaterials.2017.01.025] [PMID:  28182958] 
[88] 
Li W, Liu Z, Fontana F, et al. Tailoring porous silicon for biomedical applications: from drug delivery to cancer immunotherapy. Adv Mater  2018; 30(24)e1703740
[http://dx.doi.org/10.1002/adma.201703740] [PMID:  29534311] 
[89] 
Serda RE, Godin B, Blanco E, Chiappini C, Ferrari M. Multi-stage delivery nano-particle systems for therapeutic applications. Biochim Biophys Acta  2011; 1810(3): 317-29.
[http://dx.doi.org/10.1016/j.bbagen.2010.05.004] [PMID:  20493927] 
[90] 
Tasciotti E, Liu X, Bhavane R, et al. Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat Nanotechnol  2008; 3(3): 151-7.
[http://dx.doi.org/10.1038/nnano.2008.34] [PMID:  18654487] 
[91] 
Santos HA, Bimbo LM, Lehto VP, Airaksinen AJ, Salonen J, Hirvonen J. Multifunctional porous silicon for therapeutic drug delivery and imaging. Curr Drug Discov Technol  2011; 8(3): 228-49.
[http://dx.doi.org/10.2174/157016311796799053] [PMID:  21291407] 
[92] 
Almeida PV, Shahbazi MA, Mäkilä E, et al. Amine-modified hyaluronic acid-functionalized porous silicon nanoparticles for targeting breast cancer tumors. Nanoscale  2014; 6(17): 10377-87.
[http://dx.doi.org/10.1039/C4NR02187H] [PMID:  25074521] 
[93] 
Li Z, Zhang H, Han J, Chen Y, Lin H, Yang T. Surface nanopore engineering of 2D MXenes for targeted and synergistic multitherapies of hepatocellular carcinoma. Adv Mater  2018; 30(25)e1706981
[http://dx.doi.org/10.1002/adma.201706981] [PMID:  29663543] 
[94] 
Lee SW, Hosokawa K, Kim S, et al. A Highly sensitive porous silicon (P-Si)-based human kallikrein 2 (hK2) immunoassay platform toward accurate diagnosis of prostate cancer. Sensors (Basel)  2015; 15(5): 11972-87.
[http://dx.doi.org/10.3390/s150511972] [PMID:  26007739] 
[95] 
Lei C, Liu P, Chen B, et al. Local release of highly loaded antibodies from functionalized nanoporous support for cancer immunotherapy. J Am Chem Soc  2010; 132(20): 6906-7.
[http://dx.doi.org/10.1021/ja102414t] [PMID:  20433206] 
[96] 
Song J, Yang X, Yang Z, et al. Rational design of branched nanoporous gold nanoshells with enhanced physico-optical properties for optical imaging and cancer therapy. ACS Nano  2017; 11(6): 6102-13.
[http://dx.doi.org/10.1021/acsnano.7b02048] [PMID:  28605594] 
[97] 
Feng K-J, Yang Y-H, Wang Z-J, Jiang J-H, Shen G-L, Yu R-Q. A nano-porous CeO(2)/Chitosan composite film as the immobilization matrix for colorectal cancer DNA sequence-selective electrochemical biosensor. Talanta  2006; 70(3): 561-5.
[http://dx.doi.org/10.1016/j.talanta.2006.01.009] [PMID:  18970808] 
Cite As
Current Pharmaceutical Design

Strategies for Conjugation of Biomolecules to Nanoparticles as Tumor Targeting Agents

Abstract
